WO2003033696A1 - Compose antisens vegf - Google Patents

Compose antisens vegf Download PDF

Info

Publication number
WO2003033696A1
WO2003033696A1 PCT/JP2002/010796 JP0210796W WO03033696A1 WO 2003033696 A1 WO2003033696 A1 WO 2003033696A1 JP 0210796 W JP0210796 W JP 0210796W WO 03033696 A1 WO03033696 A1 WO 03033696A1
Authority
WO
WIPO (PCT)
Prior art keywords
antisense compound
vegf antisense
different
same
vegf
Prior art date
Application number
PCT/JP2002/010796
Other languages
English (en)
Japanese (ja)
Inventor
Makoto Koizumi
Koji Morita
Original Assignee
Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Company, Limited filed Critical Sankyo Company, Limited
Publication of WO2003033696A1 publication Critical patent/WO2003033696A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé représenté par la formule générale HO-B1-B2-B3-B4-B5-B6-B7-B8-B9-B10-B11-B12-B13-B14B15-B16-B17-B18-B19-B20-B21-B22-H (dans laquelle B1 à B3, B8, B11 et B20 peuvent être identiques ou différents et représentent chacun Cp etc. ; B4, B5, B7, B9, B12, B14 à B16 et B21 peuvent être identiques ou différents et représentent chacun Ap etc. ; B6, B10, B13 et B17 peuvent être identique ou différents et représentent chacun Gp etc. ; B18 et B19 peuvent être identiques ou différents et représentent chacun Tp etc. ; et B22 représente Tt etc. ), ainsi qu'un sel pharmacologiquement acceptable de ce composé.
PCT/JP2002/010796 2001-10-18 2002-10-17 Compose antisens vegf WO2003033696A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001/320096 2001-10-18
JP2001320096 2001-10-18

Publications (1)

Publication Number Publication Date
WO2003033696A1 true WO2003033696A1 (fr) 2003-04-24

Family

ID=19137535

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/010796 WO2003033696A1 (fr) 2001-10-18 2002-10-17 Compose antisens vegf

Country Status (1)

Country Link
WO (1) WO2003033696A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039352A1 (fr) * 1997-03-07 1998-09-11 Takeshi Imanishi Nouveaux analogues de bicyclonucleoside et d'oligonucleotide
WO1999014226A2 (fr) * 1997-09-12 1999-03-25 Exiqon A/S Analogues d'oligonucleotides
WO2000047599A1 (fr) * 1999-02-12 2000-08-17 Sankyo Company, Limited Nouveaux analogues de nucleosides et d'oligonucleotides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039352A1 (fr) * 1997-03-07 1998-09-11 Takeshi Imanishi Nouveaux analogues de bicyclonucleoside et d'oligonucleotide
WO1999014226A2 (fr) * 1997-09-12 1999-03-25 Exiqon A/S Analogues d'oligonucleotides
WO2000047599A1 (fr) * 1999-02-12 2000-08-17 Sankyo Company, Limited Nouveaux analogues de nucleosides et d'oligonucleotides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHRISTENSEN U. ET AL.: "Stopped-flow kinetics of locked nucleic acid(LNA)-oligonucleotide duplex formation: studies of LNA-DNA and DNA-DNA interactions", BIOCHEM. J., vol. 354, no. 3, 15 March 2001 (2001-03-15), pages 481 - 484, XP002971047 *
KUMAR R. ET AL.: "The first analogues of LNA(locked nucleic acids): phosphorothioate-LNA and 2'-THIO-LNA", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 8, no. 16, 1998, pages 2219 - 2222, XP002094302 *
NOMURA M. ET AL.: "Possible participation of autocrine and paracrine vascular endotherial growth factors in hypoxia-induced proliferation of endotherial cells and pericytes", J. BIOL. CHEM., vol. 270, no. 47, 1995, pages 28316 - 28324, XP002915173 *
SATOSHI OBIKA: "Tobu rittai haiza o kotei shita jinko nucleoside oyobi oligonucleotide-rui no gosei to sono tokusei", JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 120, no. 2, 2000, pages 147 - 158, XP002971048 *

Similar Documents

Publication Publication Date Title
WO2005009539A3 (fr) Composes pour l'inflammation et utilisations liees au systeme immunitaire
WO2009014100A1 (fr) INDUCTEUR DE PROTÉINE p27
WO2006034402A3 (fr) Composes pour l'inflammation et applications associees aux troubles immuns
HK1071510A1 (en) Acetylene derivatives having mglur 5 antagonistic activity
CA2497074A1 (fr) Ketoenoles spirocycliques substitues
WO2006007384A3 (fr) Antibiotiques contenant des complexes de l'acide borinique, et leur procede d'utilisation
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
WO2007117465A3 (fr) Composés d'indazole
WO2001014376A8 (fr) Nouveaux composes spiro
WO2002062775A1 (fr) Dérivé de 2-acylaminothiazole ou son sel
WO2004012759A3 (fr) Utilisation de l'erythropoietine
HK1090647A1 (en) Oxazolidinone-quinolone hybrid antibiotics
DE602004006994D1 (en) 3-aryloxy und 3-heteroaryloxy substituierte benzo(b) thiophene als therapeutische wirkstoffe mit pi3k aktivität
WO2003032962A3 (fr) Antibiotiques a double action
WO2007112014A3 (fr) Nouvelles combinaisons thérapeutiques pour le traitement de la dépression
MX2007000240A (es) Derivados de [1.2]-oxazin-3,5-diona y dihidropirona sustituidos con fenilo.
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
WO2006083841A3 (fr) Esters therapeutiques
PL359763A1 (en) Fungicidal combinations of active agents
MY162231A (en) Prophylactic device carrying a microbiocidal composition
WO2002017854A3 (fr) Antibiotiques cephalosporine et leurs promedicaments
WO2004043928A3 (fr) N-sulfonyl-4-methylene-amino-3-hydroxy-2-pyridones
WO2003033696A1 (fr) Compose antisens vegf
IL196418A0 (en) Thieno[3,2-c]pyridine-7-carboxylic acid derivatives
WO2005021559A3 (fr) Oxazaborolidines constituant des effecteurs bacteriens

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP